Shanghai Allist Pharmaceuticals Co., Ltd.

Shanghai Stock Exchange 688578.SS

Shanghai Allist Pharmaceuticals Co., Ltd. Gross Profit Margin for the year ending December 31, 2023: 94.55%

Shanghai Allist Pharmaceuticals Co., Ltd. Gross Profit Margin is 94.55% for the year ending December 31, 2023, a -1.50% change year over year. Gross Profit Ratio is the ratio of gross profit to net sales, indicating the percentage of revenue that exceeds the cost of goods sold and reflects the efficiency of a company in managing its production or procurement and sales.
  • Shanghai Allist Pharmaceuticals Co., Ltd. Gross Profit Margin for the year ending December 31, 2022 was 95.99%, a -2.98% change year over year.
  • Shanghai Allist Pharmaceuticals Co., Ltd. Gross Profit Margin for the year ending December 31, 2021 was 98.94%, a 39.01% change year over year.
  • Shanghai Allist Pharmaceuticals Co., Ltd. Gross Profit Margin for the year ending December 31, 2020 was 71.17%, a 24.74% change year over year.
  • Shanghai Allist Pharmaceuticals Co., Ltd. Gross Profit Margin for the year ending December 31, 2019 was 57.06%, a 63.29% change year over year.
Key data
Date Gross Profit Margin Operating Income Margin EBT Margin Net Income Margin
Market news
SV Wall Street
Shanghai Stock Exchange: 688578.SS

Shanghai Allist Pharmaceuticals Co., Ltd.

CEO Mr. Jinhao Du
IPO Date Dec. 2, 2020
Location China
Headquarters No. 268 Lingxiaohua Road
Employees 1,044
Sector Healthcare
Industries
Pharmaceuticals Biotechnology Clinical Trials
Description

Shanghai Allist Pharmaceuticals Co., Ltd. engages in the research and development of pharmaceutical products in China. It offers pharmaceuticals for the treatment of tumor and cancer diseases. The company was founded in 2004 and is based in Shanghai, China.

StockViz Staff

February 2, 2025

Any question? Send us an email